Product Description
a short interfering RNA directed at hepatic production of apolipoprotein(a), and the effect on lipoprotein(a) serum concentrations (Sourced from: https://jamanetwork.com/journals/jama/fullarticle/2811935#google_vignette)
Mechanisms of Action: siRNA
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Mexico, Netherlands, Poland, Puerto Rico, Romania, Singapore, Slovakia, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Atherosclerosis|Coronary Disease|Myocardial Infarction|Stroke
Phase 2: Other
Phase 1: Healthy Volunteers|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2051230205 | P3 |
Not yet recruiting |
Unknown |
2029-05-31 |
|
| J3L-MC-EZEF | P3 |
Recruiting |
Atherosclerosis |
2029-03-01 |
|
| J3L-MC-EZEF | P3 |
Unknown Status |
Coronary Disease|Stroke|Myocardial Infarction |
2028-12-09 |
|
| J3L-MC-EZEH | P1 |
Not yet recruiting |
Healthy Volunteers |
2026-01-01 |